0001178913-18-000726.txt : 20180228 0001178913-18-000726.hdr.sgml : 20180228 20180228161227 ACCESSION NUMBER: 0001178913-18-000726 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180227 FILED AS OF DATE: 20180228 DATE AS OF CHANGE: 20180228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stuart Iain CENTRAL INDEX KEY: 0001727756 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36621 FILM NUMBER: 18651260 MAIL ADDRESS: STREET 1: C/O FOAMIX PHARMACEUTICALS LTD. STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001606645 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 BUSINESS PHONE: 97289316233 MAIL ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 FORMER COMPANY: FORMER CONFORMED NAME: Foamix Ltd. DATE OF NAME CHANGE: 20140428 4 1 zk1821309.xml OWNERSHIP DOCUMENT X0306 4 2018-02-27 0 0001606645 Foamix Pharmaceuticals Ltd. FOMX 0001727756 Stuart Iain C/O FOAMIX PHARMACEUTICALS LTD. 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK REHOVOT L3 7670402 ISRAEL 0 1 0 0 SVP R&D Ordinary Shares 2018-02-27 4 A 0 10000 0.00 A 37000 D Options 6.35 2018-02-27 4 A 0 30000 6.35 A 2028-02-27 Ordinary Shares 30000 30000 D This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022. The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 27,000 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security and (ii) the 10,000 ordinary shares sub-ject to unvested restricted share units granted on February 27, 2018 and first reported on this Form 4. Each option represents a contingent right to purchase one ordinary share of the issuer. The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022. /s/ Ilan Hadar as attorney-in-fact for Iain Stuart 2018-02-28